It should be mentioned, moreover, that in a Swiss record linkage study (Bietry et al. 2016) statins were inversely related to cholecystectomy, with relative risks of 0.85 for current users and 0.77 for long-term users. Since gallstones are key risk factors for gallbladder cancer (Int J Cancer 2006;118:1591-1602, and are likely to play a role in extra hepatic CCA too, such a favorable impact of statins on gallstones may, at least in part, accounts for the inverse relationship with BTCs observed in the UK CPRD.
Surveillance colonoscopies account for 3 million examinations in the United States (Gastrointest Endosc 2014; 80:133-143) . This number may be increasing owing to the greater number of adenomas being detected as a result of significant improvements in the performance of colonoscopy, which include high-definition optics, better preparation procedures such as split dose preparation, and attention to quality measures such as withdrawal time. The detection of more adenomas raises the issue of whether risk stratification should be updated in individuals with index adenomas. The current paradigm divides colonoscopy findings into low risk adenomas and high risk adenomas (Gastroenterology 2012; 143:844-857) . Low-risk adenomas are 1-2 small tubular adenomas and require a 5-to 10-year follow-up. High-risk adenomas include any adenoma that is 1 cm, has villous elements or high-grade dysplasia, adenocarcinoma, and 3 adenomas of any size. Any of these polyp findings trigger a 3-year follow-up colonoscopy interval. Recently published data suggest that individuals with 3 diminutive (<6 mm) adenomas are at a lower risk than those with 3 small (6-9 mm) adenomas for metachronous advanced adenomas, the current outcome used to measure index risk (Dig Liver Dis 2018; 50:847-852) . This raises the issue of whether individuals with 3 or more diminutive adenomas have a similar metachronous risk to those with 1-2 small (< 1 cm) tubular adenomas, considered to be a low-risk group.
The current study by Kim et al retrospectively investigates the impact of polyp size and number in 5482 Korean patients undergoing screening and follow-up surveillance colonoscopies (Am J Gastroenterol 2018; 113:1855 -1861 . The aim of the study was to compare the risk of developing metachronous advance adenomas in 4 groups based on index findings: group 1, 1-2 nonadvanced adenomas; group 2, 3 diminutive (1-5 mm) nonadvanced adenomas; group 3, 3 small (6-9 mm) nonadvanced adenomas; and group 4, high-risk, advanced adenomas. The authors adjusted for covariates including age, sex, body mass index, lifestyle habits, aspirin use, and endoscopist adenoma detection rate. A surveillance examination was defined as a colonoscopy performed 1 year after the index examination.
The results demonstrate a stepwise increased risk of metachronous advanced adenomas across the 4 groups for absolute (3.9%, 5.9%, 10.6%, and 22.1%, respectively) as well as adjusted risks. Although the point estimate for the group with 3 diminutive (1-5 mm) nonadvanced adenomas was increased, the increased risk was not statistically significant (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.99-2.94). Groups 3 (3 small) and 4 (advanced adenomas) did have a statistically significant increased risk for metachronous advanced adenomas as compared with group 1 (HR, 2.76 [95% CI, 1.72-4.44] and HR, 5.23 [95% CI, 3.57-7.68], respectively). The authors concluded that there is significant variation in risk based on size of index adenomas and that the individuals in group 2 with 3 diminutive adenomas had a borderline increase in risk.
Comment. The current study provides crucial data that suggest the size of index adenomas may be important for determining the risk of metachronous advanced adenomas. Using 1-2 small nonadvanced adenomas as a reference, the authors observed that while those with 3 diminutive adenomas had a borderline risk, those with 3 small adenomas had a significantly increased risk. These data suggest that perhaps guidelines should consider the size of index adenomas, distinguishing diminutive from small, when making recommendations for individuals with small adenomas. For example, perhaps 3 diminutive adenomas might require 5-year or longer follow-up as compared with 3 small adenomas, which perhaps could require a 3-year follow-up.
However, there are some issues that need to be addressed before changes in guidelines can be made based on these data. It is not always clear when examining data like that in the current study what cutoff for metachronous risk should be used to classify index lesions as significant, mandating a closer surveillance interval. Certainly, comparing the risks among the index groups within the sample is useful. When comparing risks in the current study, the absolute risk for advanced adenomas (22.6%) was significantly higher than the risk for the other groups and clearly this group would have the highest risk. The results are less certain for the other groups. Although group 3 (3 small adenomas) had a statistically higher risk than group 1 (1-2 nonadvanced adenomas) and group 2 (3 diminutive adenomas) did not have statistical significance, there was overlap between groups 2 and 3.
Another important issue to consider is that the median interval to surveillance examination was 38 months for the low-risk group of 1-2 nonadvanced adenomas, which is shorter than the low end (60 months) of the 5-to 10-year follow-up recommended in the US guidelines. It is possible that, if the interval were appropriately longer, there might be more significant findings in this group. Then, if there were more adenomas in this low-risk group, which served as the reference, it is likely that the metachronous risk for group 2 with 3 diminutive adenomas as compared with group 1 might have been even less significant. Although this this finding would further suggest that 3 diminutive adenomas might be a low-risk group, it is only speculation. Finally, there are some other important groups that are not in this analysis, including the commonly encountered 3 adenomas with only 1 or 2 being small. It is unclear how different this group's metachronous risk would been when compared with the reference and other groups. The authors also excluded individuals with sessile serrated polyps and traditional serrated adenomas. Serrated polyps are commonly detected together with conventional adenomas, and recent data have demonstrated that sessile serrated polyps and traditional serrated adenomas that are synchronous with advanced adenomas may increase the risk for metachronous advanced adenomas (Gastroenterology 2018; 154:117-127 e2) . Thus, the results of this study would have been more informative if the authors had included patients with these serrated polyps.
There are some other limitations in the study, including the inclusion of data from a single center, a homogenous population, and the retrospective design of the study. Also, critical to the study is the sizing of the polyps and, to their credit, the authors state that the endoscopists routinely used the open forceps method to estimate size. However, it is not clear if this method was used consistently.
There are also many strong points in this study, including a large cohort of 5482 patients with a quality index and repeat colonoscopy. In addition, the authors included many important colorectal cancer risk factors as covariates including body mass index, smoking, exercise, aspirin use, and alcohol intake. Furthermore, they included the adenoma detection rate of the endoscopists performing the index and surveillance colonoscopies. This point is important because some adenomas detected during the surveillance examination might have actually been missed lesions.
Although there are some issues with generalizability and time to surveillance, the authors should be commended on an important study that does demonstrate the impact of size when examining metachronous risk of small (<1 cm) adenomas. Clearly, more studies in other populations will have to be conducted. In addition, metachronous risk for advanced adenomas is the best currently available outcome to use, but it is only a surrogate for colorectal cancer. More studies from larger databases with longer longitudinal follow-up will be needed to examine colorectal cancer risk in individuals undergoing surveillance. These will likely produce the best results for establishing risk for index lesions in adults undergoing surveillance. 
